Posac 100MG Tablet
Made in:
Brand:
Capacity:
Indications Posac is indicated in patients aged 13 years and above for the treatment of the following fungal infections: Invasive aspergillosis in patients with disease that […]
Indications
- Invasive aspergillosis in patients with disease that is refractory or intolerant to Amphotericin B or Itraconazole.
- Fusariosis in patients with disease that is refractory or intolerant to Amphotericin B.
- Chromoblastomycosis and mycetoma in patients with disease that is refractory or intolerant to Itraconazole.
- Coccidioidomycosis in patients with disease that is refractory or intolerant to Amphotericin B, Itraconazole or Fluconazole or in patients who are intolerant of these medicinal products.
Also indicated for prophylaxis of invasive fungal infections in the following patients:
- Patients receiving remission-induction chemotherapy for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections.
- Hematopoietic Stem Cell Transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
Loading Dose: 300 mg (3 Tablets) twice a day on the first day.
Maintenance Dose: 300 mg (3 Tablets) once a day from the second day.
Duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression and clinical response.
Use in Special Populations
Geriatric Use: No dose adjustment is necessary for geriatric patients.
Hepatic Impairment: Posac should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that Posac plasma levels may be higher in these patients. Liver function tests should be evaluated at the start of and during the course of Posac therapy.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR: 50-80 mL/min/1.73 m2) to moderate renal impairment (eGFR: 20-49 mL/min/1.73 m2). Patients with severe renal impairment should be monitored closely for breakthrough fungal infections.
Therapeutic Class
Storage Conditions
| Capacity | 10 Tablets (1 Strip) |
|---|








Reviews
There are no reviews yet.